Inventiva Receives a Financing of ~$38.79M from Investors for the Development of Its Pipeline
Shots:
- The financing consists of two transactions: (i) The Capital Increase reserved to specified categories of investors for an amount of $33.26M through the issuance of 9,618,638 newly-issued ordinary shares and (ii) the Royalty Certificates for an amount of $5.54M
- The 95% fund from Capital Increase is expected to be used in the P-III study of lanifibranor in NASH and 5% for other pre-clinical and clinical programs
- Following the completion of the Capital Increase and the issuance of Royalty Certificates, the company will have sufficient net working capital to meet its current obligations until the beginning of Q2’24. The funding was led by Qatar Holding (new investor), Sofinnova Partner and Yiheng Capital (existing investor)
Ref: Globe Newswire | Image: Inventiva
Related News:- Inventiva Reports Investigator-Initiated P-II Trial Results of Lanifibranor for Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
